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Microbiology

Selection and Characterization of 2',3'-Dideoxy-2',3'Didehydrothymidine (d4T)-Resistant Mutants of Feline
Immunodeficiency Virus (80 pp)

Director: Thomas W. North
A step-wise selection protocol was used to obtain two
mutants of feline immunodeficiency virus (FIV) resistant to 2',3'dideoxy-2',3'-didehydrothymidine (d4T). These mutants were
selected by passage of FIV 34TF10 (a molecular clone of FIV
Petaluma) in Increasing concentrations of d4T, beginning at 12.5 |J.M
in the initial round and increasing the concentration 2-fold in each
subsequent round. Two mutants able to replicate in 100 fiM d4T (8
times of the IC50) were obtained and plaque-purified.
Both mutants were 3 to 4-fold resistant to d4T, relative to
FIV 34TF10. These mutants were cross-resistant to 3'-azido-3'deoxythymidine (AZT), 3'-fluoro-2',3'-dideoxythymidine (FLT), 2',3'dideoxycytidine
(ddC),
2',3'-dideoxyinosine
(ddl),
9-(2phosphonylmethoxyethyl)-adenine (PMEA), and were highly resistant
to phosphonoformic acid (PFA). The mutant phenotype was stable, as
the virus remained d4T-resistant even after passage in the absence
of d4T for three rounds. Reverse transcriptase (RT) was purified
from one of these mutants, D4R-3c. This RT was 5-fold resistant to
the 5'-triphosphate of d4T (d4TTP), relative to wild-type FIV RT.
Sequence analysis of the RT-encoding region of the pol gene revealed
a point mutation at position 2474 resulting in a Val to lie mutation
at amino acid 47 of the FIV RT. Site-directed mutagenesis was
performed and showed that this amino acid change was responsible
for the d4T-resistance.
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INTRODUCTION

GENERAL INTRODUCTION
In the nnid-1980s, announcements in Paris and in Bethesda,
Maryland, declared that a retrovirus had been isolated that was the
etiologic agent of the acquired immune deficiency syndrome (AIDS)
which poses a serious challenge to modern medicine. The retrovirus
is known today as the human immunodeficiency virus type-1 (HIV-1).
The virus targets cells of the immune system, specifically the
helper T lymphocytes. HIV infection results in immunosuppression,
rendering the patient susceptible to opportunistic infections. These
infections lead to a high incidence of morbidity and mortality (40).
HIV-1 is currently the number two killer of people between the ages
of 25 and 45 years. Over 13 million people are presently infected
with the virus and predictions for the future are frightening (50). To
conquer this disease, two strategies have been undertaken: a
protective vaccine or effective drugs able to block the life cycle of
the virus. It is widely agreed that an AIDS vaccine is necessary, but
this virus is in a state of antigenic flux, and consequently,
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protective vaccine development has been difficult. To date, no
protective vaccine has been developed. In contrast, modest success
has been achieved with chemotherapy. Antiviral agents are usually
targeted at a receptor, enzyme or another viral component that is
required for replication. There are various events in the replicative
cycle of HIV that could be considered as targets for
chemotherapeutic intervention: 1) virus adsorption to the cell
membrane; 2) fusion between the viral envelope and the cell
membrane; 3) uncoating of the viral nucleocapsid; 4) reverse
transcription

of the viral RNA to proviral DNA; 5) integration of the

pro viral DNA into the cellular genome; 6) transcription of the
proviral DNA to RNA, a process that is regulated by transcriptional
transactivators (i.e., TAT); 7) conversion of the viral precursor
mRNA to mature mRNA, a process that is regulated by
posttranscriptional transactivators (i.e., REV); 8) posttranslational
processing of the viral precursor proteins by proteolysis,
glycosylation, and myristoylation; and 9) virion assembly and
release ("budding") (12, 44). To date, numerous compounds have been
reported to inhibit the replication of HIV in vitro, yet only relatively
few agents have at this time been formally licensed (in the United
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States) for clinical use in the treatment of AIDS. These are
zidovudine (3'-azido-2',3'-dideoxythymidine, AZT) (34), didanosine
(2',3'-dideoxyinosine, ddl) (17), zaicitabine (2',3'-dideoxycytidine,
ddC) (73), stavudine (2',3'-didehydro-2',3'-dideoxythymidine, d4T)
(2)

and (-)-B-2',3'-dideoxy-3'-thiacytidine (3TC) (55). Several

protease inhibitors have been approved also. However, variants of
HIV-1 that are resistant to these drugs, or combinations of these
drugs, emerge in treated patients and are believed to be responsible
for drug failures (18,35,59,63,64,71). The problem of resistance is
not limited to nucleoside analogs. Mutants of HIV-1 resistant to
non-nucleoside inhibitor of RT, such as nevirapine (60), or to
protease inhibitors (10,28) have been isolated from treated patients.
Numerous HIV-1 mutants resistant to RT or protease inhibitors have
also been selected in cell culture systems (19,20,30,36,51).
Resistance of HIV-1 to RT and protease inhibitors has been traced to
mutations in genes encoding the HIV-1 RT and protease, respectively
(62). In order to develop successful AIDS therapy, it will be
necessary to understand mechanisms of resistance and to develop
strategies to combat it.
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Animal models of AIDS are essential for understanding the
pathogenesis of retrovirus-induced immune deficiency and
encephalopathy, and for development and testing of new therapies
and vaccines. Many viruses and animal models have been evaluated
for use as AIDS models, including simian immunodeficiency virus
(SIV), avian retroviruses, murine retroviruses, severe combinedimmunodeficiency (SCID) mouse models, lentiviruses in sheep, goats,
horses and cows, HIV type-2 (HIV-2) infection in macaques, and
feline immunodeficiency virus (FIV) infection of cats. Since its
discovery in 1987 (53), FIV has become recognized as a valuable
animal model for AIDS studies. The advantages of this model are 1)
the FIV biology, infection cycle, and disease closely mimic those of
HIV and human AIDS, 2) cats are relatively inexpensive compared to
nonhuman primates, 3) FIV is safe to work with since it is not
infectious to human, and 4) in vitro and in vivo

systems are

available and their versatility facilitates studies of pathogenesis,
antiviral therapies, protective vaccines, and drug resistance.

5

FELINE IMMUNODEFICIENCY VIRUS
Feline immunodeficiency virus (FIV) is a lentivirus that causes an
immune deficiency in domestic cats that is very similar to human
AIDS and which can also be induced experimentally in specificpathogen-free cats (SPF) (70,74). FIV was first described by Neils
Pedersen and co-workers in 1987. Subsequent investigations have
shown that

FIV is an important health problem for domestic cats

throughout the world.

The expectation that FIV would become a

leading animal model for HIV studies has been fulfilled.

The virion.

The mature extracellular FIV virion is spherical to

ellipsoid, 100 to 125 nm in diameter, and bordered by an outer
envelope with poorly

defined short projections or knobs. The

elongated core is composed of a conical shell that surrounds an
eccentric electron-dense nucleoid. A polygonal electron-lucent halo
is often visible between the core and
inside the envelope (45,53,69,75). Each

a granular layer found just
FIV virion contains: the

envelope (Env) glycoproteins: surface (SU) protein, and
transmembrane (TM) glycoprotein; the internal protein (Gag)
components: the matrix (MA) protein, capsid (CA) protein and

nucleocapsid (NC) protein; and the Pol proteins including protease
(PR), RT, dUTPase (DU) and integrase (IN). FIV virions also contain
two copies of the positive-stranded, polyadenylated RNA genome
(about 9200 bases long). As is typical of retroviruses, in the FIV
virion Gag proteins are about 20-fold more abundant than Pol
proteins (16) (Fig.1).

Life cycle.

FIV is an enveloped, single-stranded RNA virus that

belongs to the lentivirus family. FIV and HIV-1 share the
prototypical life cycle of a retrovirus (Fig. 2). The virus is first
adsorbed by a receptor on the host cell membrane. HIV binds to T
cells surface receptor, the CD4 molecule (CD9 in FIV), and by
interacting

with this

and at

least

one

other cell surface

molecule, a conformational change occurs in the

envelope

glycoproteins to reveal the hydrophobic sequence of the
transmembrane envelope protein. This leads to a fusion of the viral
envelop with the cell membrane and delivery of the viral capsid into
the cytoplasm of the cell (38). Within the capsid structure the
diploid RNA genome is reverse transcribed by the viral RT. RT is the
viral-encoded RNA-dependent DNA polymerase responsible for

synthesis of a DNA copy of the viral RNA genome. This generates an
RNA/DNA heteroduplex containing

a complete DNA copy of the viral

genes. Subsequently, the RNA is degraded by the RNase H activity of
RT, and a DNA duplex is synthesized by RT. The double-stranded DNA
genome is then integrated into the host genome as a provirus (68).
The provirus may remain dormant until some, as of yet unknown,
factor(s) stimulates the provirus into active replication to produce
infectious virus particles. The cell will then produce viral RNA and
proteins. These progeny viruses assemble and are released from the
cell surface by budding. The virus can then infect other cells.

Genome structure and organization.

FIV diverges from other

lentiviruses throughout the genome. Its sequence organization,
however, is similar in complexity to that of other lentiviruses
(Fig.3). Three large open reading frames (ORFs), gag, pol, and env,
encode the internal structural proteins , the RT and other viral
enzymes, and the envelope proteins, respectively.

FIV also has

several small ORFs that encode regulatory proteins. The provirus
contains two long terminal repeat (LTR) elements, one at each end of
the genome, which accommodate multiple regulatory sequences.
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The gag

gene, spanning approximately nucleotides 600 to 2000, is

initially translated to yield a precursor polypeptide of about 50 kDa
that is posttranslationally cleaved by the viral protease (PR) (14,65)
to yield (amino to carboxy order) three functional core proteins.
They are mature MA, CA, and NC proteins. The MA is approximately
15 kDa , which has recently been shown to be
The CA protein is the largest gag

myristoylated (16).

product. It is the major core

protein, a 25 kDa group-associated antigen. The NC protein is
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approximately 10 kDa, which contains motifs characteristic of
retroviral nucleic acid binding proteins and is believed to be
associated with the genomic RNA to form the ribonucleoprotein
(14,65).

The pol gene is an enzyme cassette, which spans nucleotides
1900 to 5200 and, thus, overlaps the gag gene by 109 nucleotides.
Pol is in a -1 reading frame with respect to that of the gag gene
and is translated as a Gag-Pol fusion polyprotein produced by
ribosomal frameshifting (8), as in other retroviruses. The Gag-Pol
fusion precursor protein is eventually processed into the
functionally mature enzymes during virus assembly. The Pol portion
of the precursor polyprotein is eventually cleaved into PR, RT, DU,
and an endonuclease or integrase, most likely due to autodigestion
(15,16).

The primary translation product of the env

gene (which spans

nucleotides 6250 to 8850) is a precursor glycoprotein of 145 to 150
kDa (gp145) that is rapidly reduced in size to a molecule of 139 kDa
(gp130). gp130 is subsequently processed into the mature
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glycoproteins SU (gp95) and TM (gp40) of the viral envelope by
proteolytic cleavage in the Golgi complex (66).

Moreover, FIV also contains regulatory genes. There y and vif are
the only two that have been characterized to some extent.

Biochemical features of RT.

The RT of FIV has been purified

and extensively characterized by North, et al. FIV RT consists of two
polypeptides with common N-termini, a 66-kDa (p66), and a 51-kDa
subunit. Both subunits are present in equimolar amounts (46,49). FIV
RT p51 is generated by cleavage of the RNase H domain (pi 5) at the
C-terminus of FIV RT p66 by the virus-encoded protease. FIV RT is
very similar to HIV-1 RT in physical properties, catalytic activity
and sensitivity to several RT inhibitors (11,47,48,49). Both enzyme
have comparable requirements for Mg2+ and similar template
specificities (49). From sequence analysis, HIV-1 RT and FIV RT
share 63% identity at the nucleotide level and 48% identity and 67%
similarity at the amino acid level, respectively (1).

The first five antivirals approved for AIDS therapy are targeted
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to RT. RT has become an excellent target for attempts to arrest the
proliferation of HIV -1 for several reasons: a) it is a crucial enzyme
in the viral replication cycle; b) its properties are quite different
from those of the other cellular DNA polymerases; and c) it is active
in the cytoplasmic compartment of the infected cell, separate from
the nuclear and mitochondrial DNA polymerases. FIV and HIV-1 RTs
are nearly identical in susceptibility to several nucleotide analogs
that are active forms of antiviral drugs, including 2',3'dideoxythymidine 5'-triphosphate (ddTTP), AZTTP, 2',3'dideoxycytidine 5'-triphosphate (ddCTP), 2',3'-dideoxy-2',3'didehydrothymidine 5'-triphosphate (d4TTP). They are also similar
in susceptibility to 3'-fluoro-3'-deoxythymidine 5'-triphosphate
(3'-F-dTTP), 3'-amino-3'-deoxythymidine (3'-NH2-dTTP) and two
noncompetitive inhibitors PFA and phosphonoacetate (PAA) (48).
Because of the similarities of FIV and HIV-1 RTs, FIV has been
extremely useful as a model for RT-targeted antivirals.

Transmission and pathogenesis.

In contrast to HIV-1, FIV is not

efficiently transmitted sexually (54). FIV is usually spread through
an infected cat biting or scratching an uninfected cat.

Experimentally-infected female cats have been shown to transmit
the virus to their offspring (72), although naturally-infected cats
transmitting virus to offspring has not been reported. Interspecies
transmission does not occur with FIV. This species specificity of
FIV is characteristic of retroviruses. No FIV antibodies have been
detected in humans who have had extensive contact with FIVinfected cats, including individuals who have been bitten. This
shows that FIV is a safe model for AIDS studies.

The pathological effects observed in FIV-infected cats may be
both a direct consequence of FIV infection and secondary to the
immunodeficiency state caused by the virus. From observations of
field and experimentally-infected SPF cats, it has become evident
that FIV infections can be divided into several sequential steps. On
the basis of the type and severity of clinical signs, a staging of FIVinfected cats into five phases which parallels the classification
systems used for HIV-induced pathology, a) Acute phase. In some
cases primary infection is clinically silent.

More commonly, it

manifests itself as a transient illness (1 to 4 weeks) with
generalized lymphadenopathy, mild pyrexia dullness, neutropenia ,
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acute diarrhea, and mild upper respiratory symptoms (8). b)
Asymptomatic phase. During this latent stage of infection, virus can
be isolated from the blood, but no clinical signs are apparent, c)
Persistent generalized lymphadenopathy (PGL). In this stage the
animal exhibits vague signs of disease, including recurrent fevers,
anorexia, weight loss, or nonspecific behavioral changes but without
any obvious indications of secondary or opportunistic infections, d)
AIDS-related complex (ARC). Cats in this category usually present
with chronic secondary infections of the oral cavity, upper
respiratory tract, and other body sites but no opportunistic
infections. Most cases diagnosed as ARC progress to feline AIDS
(FAIDS) after variable time intervals (26,27,52). e) FAIDS. It is
similar in many respects to full-blown AIDS of humans. Cats suffer
from severe secondary infections listed above and from neoplastic
and neurologic disorders. Infections are often multiple, sustained by
opportunistic agents, and resistant to treatment. Most animals
present with a marked loss of body weight as well as severe anemia
and leukopenia. The clinical picture worsens rapidly, and once the
diagnosis is made, the mean survival time is usually less than 1
year, in spite of supportive therapy (27,52). In addition to the above
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stages, Pedersen (52) has proposed a sixth group to include cats
presenting with miscellaneous disorders (neurological, neoplastic,
ocular, and immunologically mediated, etc.) in the absence of other
manifestations that, if present, would allow their inclusion in the
previous classification.

Treatment.

Currently available anti-HIV therapies are only

partially effective in controlling virus replication. Since RT plays an
important role in replication of both HIV-1 and FIV, it is an
attractive target for antiviral chemotherapy. RT inhibitors can be
divided into two groups, depending on whether they are targeted at
the substrate binding site or nonsubstrate binding site (13). To the
first group belong the 2',3'-dideoxynucleosides (i.e., ddC, ddl), 3'azido-2',3'-dideoxynucleosides (i.e.,AZT), 3'-fluoro-2',3dideoxynucleosides (i.e.,FLT), 2',3'-didehydro-2',3'dideoxynucleosides (i.e., d4T, d4C) and carbocyclic derivatives
thereof (i.e., carbovir), 2'-fluoro-ara-2',3'-dideoxynucleosides, 1,3dioxolane derivatives (i.e., 2',3'-dideoxyl-3'-thiacytidine),
oxetanocin analogues and carbocyclic derivatives thereof (i.e.,
cyclobut-G) and the PMEA and 9-(3-fluoro-2-
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phosphonylmethoxypropyl)adenine (FPMPA) derivatives. These
compounds need to be phosphorylated intracellularly to their
triphosphate forms before they act as competitive inhibitors or
alternate substrates (chain terminators) of RT (Fig.4). The second
group includes the tetrahydro-imidazo[4,5,l-jk][1,4]-benzodiazepin2(1H)one (TIBO), 1-[(2-hydroxyethoxy)-methyl]-6(phenylthio)thymine (HEPT), djpyrido[3,2-b:2',3'-e]-[1,4]diazepin-6one (nevirapine) and pyridin-2(1 H)one derivatives, which interact as
such, noncompetltively, with a specific allosteric binding site of
HIV-1RT. Members of this group do not inhibit FIV.

In addition, several protease inhibitors are also being studied. To
date, the FDA has approved five nucleoside analogs (AZT, ddl, ddC,
d4T and 3TC) and two protease inhibitors for treatment of humans
with AIDS. Since both HIV-1 and FIV RT are susceptible to the
nucleoside analog inhibitors, FIV is an excellent choice as an animal
model for drug resistance studies of viral mutants resistant to
these drugs.
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Fig 4. Nucleoside and pyropliospliate analogs with antiviral
activities.
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Drug resistance.

The rapid emergence of drug-resistant

variants of HIV-1 is a significant impediment

to the treatments of

AIDS. Clinically, drug-resistant mutants arise in AIDS patients
treated with nucleoside analogs, protease inhibitors, etc. The first
reported lentivirus mutants with drug-resistant phenotypes that
were selected in vitro were AZT-resistant mutants of FIV (57).
These mutants were phenotypically similar to AZT-resistant
mutants of HIV-1 isolated from patients (35,57). Mutants of FIV that
are resistant to ddl (21), ddC (43) or the combination of AZT plus ddl
(21) have been subsequently reported. Resistance to AZT, ddC have
been traced to mutations within the RT-encoding region of the pol
gene (58,43).

The d4T is a thymidine analogue with an unsaturated bond
between the 2'- and 3'-carbons of the sugar moiety. Like AZT, it is a
potent inhibitor of HIV replication in several cell lines and prevents
the cytopathic effects of the viral infection (4,5,6,25,39,40,41). d4T
is metabolized in cells to the triphosphate form (d4TTP), which is a
potent inhibitor of the viral RT in a manner that is competitive with
respect to the natural substrate, dTTP. D4TTP also serves as a
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substrate for incorporation into DNA, whicli causes chain
termination (24). d4T has shown efficacy in patients with AIDS and
is less toxic to host cells than AZT (22,40,41,42). Cells take up d4T
by nonfacilitated diffusion (3) and then

phosphorylate it by cellular

enzymes to its mono-, di-, and triphosphates. Unlike AZT, d4T has a
low affinity to thymidine kinase in several cell lines (6,42). Thus,
the conversion to its monophosphate by this enzyme is the ratelimiting step in its metabolic activation pathway by triphosphate
(25,42).

There are no clinical reports in the literature of documented
mutations in the HIV-1 RT conferring decreased sensitivity to d4T.
Clinical isolates highly resistant to AZT were found to remain
sensitive to d4T (35). Furthermore, recombinant viruses resistant to
AZT, ddl, ddC or 3TC are not cross-resistant to d4T (33). In view of
the clinical potential of d4T, it is important to determine how
readily viral resistance is likely to arise and what cross-resistance
to other inhibitors might be expected. Lacey and Larder have
selected mutants of HIV-1 that are resistant to d4T in vitro (33).
These variants have a mutation at codon 75 in the RT-encoding

21
region of the HIV-1 pol gene that results in substitution of Thr for
Val-75 of the HIV-1 RT. This mutation confers moderate (seven
fold) d4T-resistance and cross-resistance to both ddl and ddC.

In order to study drug resistance, it is important to have a
defined system that is safe and easily manipulated. It is also useful
to have a system which allows for timely selection of drugresistant mutants. FIV has a well-defined cell culture system and
drug-resistant mutants can be readily selected (59). In addition,
there is a molecular clone of FIV, FIV 34TF10, with a known
sequence (67). This molecular clone provides a defined genetic
system to study mutations. Using FIV as an animal model, many
questions pertaining to drug resistance can be addressed. Not only
can drug-resistant mutants be selected and characterized in a cell
culture system, but the pathogenicity and infectivity of drugresistant mutants can be determined in cats (7). In the work
described here we have utilized the FIV system to characterize
resistance to d4T.
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SPECIFIC GOALS

The goal of this study was to select and characterize d4Tresistant mutants of FIV 34TF10. Specific objectives were to select
variants of FIV that appear when virus replication occurs in the
presence of d4T, to determine whether these mutants are crossresistant

to

other

antivirals, and

to

determine

whether

d4T-

resistance is due to alterations in RT by characterization of RT
purified from the mutant and by DNA sequence analysis and sitedirected mutagenesis.

MATERIALS AND METHODS

CHEMICALS. Triton X-100, dTTP, aminoethyl carbazole, ddC and
phosphonoformic acid (RFA) were purchased from Sigma Chemical
Co., St. Louis, MO. AZT and the 5'-triphosphate of AZT (AZTTP) were
provided by the Burroughs Wellcome Co., Research Triangle Park, NC.
The d4T and the 5'-triphosphate of d4T (d4TTP) were provided by
Bristol-Myers Squibb Co., Wallingford, CT. PMEA was provided by
Gilead Sciences, Inc., Foster City, CA. The ddl was provided by the
Developmental Therapeutics branch. Division of AIDS, National
Institute of Allergy and Infectious Diseases. The 3'-fluoro-2',3'dideoxythymidine (FLT) was obtained form the Lederle Laboratories
Division of American Cyanamid Co., Pearl River, NY. Poly (rA)oligo(dT)io was purchased from Pharmacia LKB, Piscataway, NJ.
Nuclease-free bovine serum albumin (BSA) was obtained from
Boehringer Mannheim, Indianapolis, IN. DEAE-cellulose DE52 and
phosphocellulose P11 were purchased from Whatman, Hillsboro, OR.
International Bio Technologies (IBI) phenol for DNA extractions was
purchased from VWR Scientific. GeneAmp PCR Core
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Reagents were purchased from Perkin Elmer Cetus, Norwalk, CT. The
Taq DyeDeoxyTM Terminator Cycle Sequencing Kit was purchased
from Applied Biosystems, Foster City, CA. EcoRI was purchased
from Promega, Madison, Wl. and A/s/l was from American Applied
Biotechnology, Aurora, CO. T4 DNA ligase was from New England
Biolabs, Beverly, MA. All other chemicals were reagent grade or
better.

ISOTOPE. The [Methyl-3H]dTTP was purchased from Dupont-New
England Nuclear, Boston, MA.

CELLS AND VIRUS.

Virus produced from a molecular clone of the

Petaluma strain of FIV, 34TF10 (67), was used as wild-type FIV for
these studies. Wild-type and mutant strains of FIV were grown and
maintained in Crandell feline kidney (CrFK) cells. Uninfected and
infected cells were grown in L & M medium which was composed of
equal parts of Leibovitz L-15 and Dulbecco's Modified Eagle Medium
(Gibco BRL Life Technologies, Inc. Grand Island, NY.), supplemented
with 100 U of penicillin per ml, 100 jig of streptomycin per ml, 2.0
mM L-glutamine and 10% fetal bovine serum (FBS). FBS was heat
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inactivated for 30 min. at 56°C. All cultures were maintained at
37°C in a humidified 5% CO2 atmosphere. The CrFK cells used were
passaged 6 or fewer times after they were obtained from the
American Type Culture Collection (Rockville, MD.) because we have
observed that at high passage number in L & M medium these cells
lose ability to support FIV replication (32). The d4T-resistant
mutants of FIV were maintained in medium containing d4T, and the
medium was replaced with fresh medium containing the appropriate
concentration of d4T every 2 days.

Virus stocks were prepared from medium containing extracellular
virus released from CrFK cells that had been infected with FIV for
more than 21 days. Medium was removed from cultures that were
near confluence and cells were removed from the medium by
centrifugation at 500 X g for 10 min. The supernatant was stored at
-80°C in medium containing 10% dimethyl sulfoxide. Aliquots of
these stocks were thawed and used to infect CrFK cells for
subsequent studies.
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FOCAL INFECTIVITY ASSAY (FIA). The FIA was developed in this
lab by Remington et al. (57) and is a modification of the FIA
developed by Chesebro and Wehrly to quantitate HIV-1 (9). In this
assay, CrFK cells were seeded into 24-well plates at a density of
1.5 X 104 cells per well and incubated for 1 h at 37°C in growth
medium or growth medium containing appropriate concentration of
drug. This incubation was to allow the cells to convert drugs to their
active forms. These cells were infected with 30 to 60 focusforming units (FFU) of wild-type or mutant FIV per well, then
incubated at 37°C for 4-5 days to allow cells to grow to confluence.
The medium was replaced with fresh medium and appropriate drug
concentration every 2 days. When the cells reached confluence, the
medium was aspirated and the cells were fixed with methanol for
five minutes. The cells were then washed twice with TNE (0.01 M
Tris-HCI, pH 7.5, containing 0.15 M NaCI and 0.002 M EDTA), and once
with TNE that contained 1% adult bovine serum. Immunostaining was
performed by incubating the fixed cells for 30 min with 0.2 ml of a
1/200 dilution of polyclonal antiserum that had been obtained from
FIV-infected specific-pathogen-free cats. Cells were washed twice
with TNE that contained 1 % serum to remove excess antiserum and
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were then incubated for 40-60 min with 0.2 ml of a 1/600 dilution
of horseradish peroxidase-conjugated goat anti-cat IgG (OrganonTeknika, Durham, NC ). The cells were again washed with TNE and
foci of infected cells were then stained by reacting the antibodybound monolayers for 20 min in the dark with a solution of
aminoethyl carbazole (1 part 4 mg/ml aminoethyl carbazole in
dimethylformamide per 19 parts 0.05 M sodium acetate buffer, pH
5), containing 30% H2O2 (1 M-l per 2 ml). After incubation, the cells
were rinsed three to five times with water and allowed to dry. Foci
appeared as groups of 4 or more infected cells (red), which is
defined as a focus of infection, against an unstained background.
Foci were examined and counted under a dissecting microscope at 10
to 40 X magnification. For visualization, light was reflected off a
piece of ground glass to reduce the refractivity of the infected cells.
For dose response curves with drugs, data were plotted as
percentage of control plaques (no drug) versus inhibitor
concentration. Concentrations required to inhibit focus formation by
50%

(IC50

values) were obtained directly from the linear portion of

these plots.
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SELECTION OF d4T-RESISTANT MUTANT.

A step-wise selection

protocol that is similar to that used by Gao et al. (19,20) and by
Larder et al. (36) to select drug-resistant variants of HIV-1 was
chosen. The initial round of selection was carried out with 12.5 iiM
d4T, which is equivalent to the

IC50

of d4T for FIV (58). The

concentration of d4T was then increased 2-fold in each subsequent
round. For the first round, two 25-cnn2 flasks of CrFK cells at 60%
confluence (about 2 XI06 cells) were pre-treated for one hour with
12.5 |j.M d4T to enable conversion of the drug to the active form.
Then CrFK cells were infected with a cell-free culture supernatant
of FIV 34TF10 at an input multiplicity of approximately 2000 focus
forming units (FFU). Medium and drug were replaced every 48 hours,
and cells were removed with trypsin and subcultured as necessary.
The cultures were monitored weekly for the presence of virus by the
FIA. By 2 to 3 weeks post-infection virus production was apparent.
Culture supernatants from each of the first-round cultures were
used to infect flasks of CrFK cells for the second round of selection
in the presence of 25 fiM d4T. Using these protocols, virus was
subsequently passaged in 25, 50, and 100 jiM d4T. In each round of
selection, virus production was apparent by 2 to 3 weeks post-

infection. After passage in 100 iiM d4T (which is approximately 8
times the

IC50

for FIV), two d4T-resistant mutants, D4R-1c and

D4R-2C were obtained. These mutants were subsequently plaquepurified.

Another selection protocol called "blast" selection was
attempted. It is essentially as described by Remington et al. (57).
Infections were carried out in the continuous presence of d4T at 100
|xM, which is

8

times the

IC50

for inhibition of FIV replication. Using

this approach, AZT, ddl and ddC-resistant mutants of FIV have been
successfully selected in the presence of drugs at concentrations 5
to 10 times higher than the

IC50.

PLAQUE-PURIFICATION OF d4T-RESISTANT MUTANTS. To
minimize potential heterogeneity within the d4T-resistant mutant
populations, plaque-purified isolates were obtained from D4R-1c
and D4R-2C. Plaque-purification of the mutant virus was carried out
with a modification of the procedure described by Remington et. al.
(58). Virus of both D4R-1c and D4R-2c were plaque-purified using
limiting dilutions of virus in the FIA. Limiting dilutions of virus
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were used to infect CrFK cells in 24-well plates in the presence of
100 |iM d4T. After 5 to 6 days, each supernatant was transferred to
a well of a new plate which had been seeded with uninfected CrFK
cells at 30% confluence in the presence of 100 |iM d4T. The original
plate was stained and examined for those wells that contained a
single focus. Corresponding wells of the subculture plate were
incubated until the cells reached confluence. The cells and
supernatant from each well which contained a single focus were
transferred to flasks and maintained in medium containing 100 jilVI
d4T. Cultures were maintained by replacing medium and drug every
two days. When they reached 100% confluence, cultures were
monitored for virus production by FIA. Several cultures yielded
virus. One from each of D4R-1c and 2c, designated D4R-3c and D4R4c, were used for further characterization.

REVERSE TRANSCRIPTASE (RT).

Reverse transcriptase (RT) was

purified from virions of FIV 34TF10 and mutant FIV by a method
developed by North et al. (49). FIV-infected CrFK cells were grown in
225-cm2 tissue culture flasks to confluence. Culture medium
containing virus was collected, cells were removed by
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centrifugation at 500 X g for 5 min, ttien the virus pelleted by
centrifugation at 41,000 X g for 60 min. The supernatant was
discarded and the pellet resuspended in 50 mM Tris-HCI, pH 7.9, 20
mM dithiothreitol (DTT), 160 mM KCI, 0-05% Triton X-100 to disrupt
virions. Nuclease-free BSA was added to a final concentration of
500 |ig/ml, and this virus lysate was stored at -80°C until
purification. For purification, the virus lysate was dialyzed three
times against 500 ml of 50 mM Tris-HCI, pH 7.9, 1 mM EDTA, 1 mM
DTT, 5% glycerol (buffer A) and then applied to a 1.5 X 30-cm column
of DEAE-cellulose. The column was washed with buffer A, and then
reverse transcriptase was eluted with a 150-ml linear gradient of
0-500 mM NaCI in buffer A. Fractions containing peak RT activity
were pooled, nuclease-free BSA was added to a final concentration
of 500 |ig/ml, and this was dialyzed three times against 500 ml of
50 mM Tris-HCI, pH 7.9, 1 mM EDTA, 1 mM DTT, 20% glycerol, 50 mM
NaCI (buffer B). This sample was then applied to a 1.5 X 30-cm
column of phosphocellulose; the column was washed with buffer B,
and then RT was eluted with a 150-ml linear gradient of 50-500 mM
NaCI in buffer B. Peak fractions were pooled and stored at -80°C.
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RT ACTIVITY ASSAY.

During purification, RT was assayed for

activity as reported previously (48,49) with poly(rA)-oligo(dT)io as
the template-primer. Reactions were typically carried out in a
volume of 50 |il and contained 50 mM Tris-HCI, pH 8.5, 10 mM DTT,
0.05% Triton X-100, 250 jig of bovine serum albumin (nuclease-free)
per ml, 6 mM MgCl2, 80 mM KCI, 20 |xM [methyl-3H]dTTP (33 jiCi/ml),
0.5 A260 units (U) of poly(rA)-oligo(dT)io per ml, and appropriate
amounts of RT. Samples containing 40 \i\ were taken at 30 min and
spotted onto filters (no. 3, 2.3-cm diameter; Whatman, Inc., Clifton,
NJ) that had been presoaked with 5% trichloroacetic acid (TCA)-1%
sodium pyrophosphate (NaPPi). Filters were dried in an oven then
washed four times (at least 1 hour each) with 5% TCA-1% NaPPi at
4°C, twice with 95% ethanol at room temperature, dried in an oven
and then counted in Liquifluor (Dupont-NEN Research Products,
Boston MA). One unit of RT is defined as the amount of enzyme
required to catalyze the incorporation of 1 nmol of dTMP per hour
into poly (rA)-oligo(dT)io at 37°C.

RT INHIBITION ASSAY.

Inhibition of RT from the d4T-resistant

mutant (D4R-3c) by d4TTP was compared to inhibition of wild-type

33
recombinant FIV RT. Double-reciprocal plots were used to determine
kinetic constants (Km and Ki) with the template-primer poly(rA)oligo(dT)io and d4TTP as the inhibitor. Reactions were typically
carried out in a volume of 50 |il and contained 50 mM Tris-HCI, pH
8.5, 10 mM DTT, 0-05% Triton X-100, 250 )ig of bovine serum albumin
(nuclease-free) per ml, 6 mM MgCl2, 80 mM KCI, varying amounts of
[methyl-3H]-dTTP (16.5, 8.25, 4.95, 3.3, 2.45, and 1.65 jxCi/ml)
corresponding to varying concentrations of dTTP (20, 10, 6, 4, 3, and
2 |iM), 0.5 A260 U of poly(rA)-oligo(dT)io per ml, varying
concentrations of d4TTP which were 0, 5, 10, 20 nM, and
appropriate amounts of RT. Samples containing 40 p.! were taken at
1 hour and spotted onto filters (no. 3, 2.3-cm diameter; Whatman,
Inc., Clifton, NJ) that had been presoaked with 5% TCA-1% NaPPi (4°
C) . Filters were washed with TCA four times (15 min each) and
twice with 95% ethanol, dried and then counted in Liquifluor
(Dupont-NEN Research products, Boston, MA).

NUCLEIC ACID PREPARATION.

Total cellular DNA containing

provirus was extracted from CrFK cells that were infected with
d4T-resistant FIV. Confluent monolayers of infected cells were
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washed three times with TBS (25 mM Tris-HCI,

pH7.4,

containing 5

mM KCI and 137 mM NaCI) and removed from flasks (cells peel from
flask wall during the third wash). Cells were pelletted by
centrifugation at 500 X g for 10 min. The cells were washed twice
with TE (10 mM Tris-HCI, pH 7.6, containing 1 mM EDTA) then
suspended in this TE buffer. Cell suspensions were treated with 0.1
mg/ml proteinase K and 0.5% SDS overnight at 37° C. The cell
lysates were then extracted three times with phenol that had been
equilibrated with 10 mM Tris-HCI, pH 7.5, containing 100 mM NaCI
and 1 mM EDTA. The aqueous phase was collected and dialyzed
against 10 mM HCI, pH 7.5, containing 100 mM NaCI and 1 mM EDTA
until the Aaeo of the dialysate was less than 0.1. The dialyzed
aqueous phase was treated with RNase A (0.1 mg/ml) at 37° C for 3
hours. The RNase A-treated aqueous phase was extracted with onehalf volume equilibrated phenol and one-half volume of
chloroform:isoamyl alcohol (24:1). The aqueous layer was removed
and extracted again with one volume of chloroform;isoamyl alcohol
(24:1). The salt concentration was adjusted by adding 1/30 volume
of 3 M sodium acetate, pH 5 to the aqueous phase. The DNA was
precipitated with three volumes of cold absolute ethanol at -20° C

overnight. The DNA was removed from the ethanol and dried in air.
The DNA was dissolved in sterile distilled water and used for
amplification by the polymerase chain reaction (PGR).

PGR AMPLIFICATION AND NUCLEOTIDE SEQUENCE ANALYSIS.
Amplification of the RT-encoding region of the pot

gene was

performed using the Perkin-Elmer/Cetus GeneAMP PGR protocol.
Each 100 jil reaction contained 10 mM Tris-HGI, pH 8.3, 50 mM KGI,
200 |iM of each dNTP (dATP, dGTP, dGTP and dTTP), 4 mM MgGl2, 0.2
|a.M of each primer, 2.5 Units of AmpHTaq ® DNA polymerase, and 10
to 20 |ig of target DNA. Reactions were overlaid with 50-100 jil of
light mineral oil. The sense primer (5'-GTA ATG TTT GTG TGT TAG
AAG ATA AGT G-3') and the reverse complement primer (5'-ATG ATA
TGG TGG ATG TTG TGA GGT-3') were synthesized in the Murdock
Molecular Biology Facility, University of Montana, Missoula, MT.
These primers were chosen to

amplify a 1763-base pair fragment

that contained nucleotides 2268 through 4031. The PGR was run for
30 cycles, each cycle comprised of 30 seconds of denaturation at
94° G, 30 seconds of annealing at 62° G and two minutes of
extension at 72° G. After PGR, product was visualized on an agarose
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gel. For this, the mineral oil was separated from the PGR products
and an aliquot of

the mixture was run on a 0.8% low-melting

agarose electrophoresis gel in 40 mM Tris acetate, pH 7.6,
containing 1 mM EDTA (61). The agarose gel and running buffer
contained 0.5 |ig/ml ethidium bromide. A 1763-base pair band was
identified by comparing the electrophoresed PGR reaction to a 1 Kb
DNA ladder (Gibco BRL, Gaithersburg, MD). The remaining PGR product
was purified using the QIAquick PGR Purification Kit, Qiagen Inc.,
Ghatsworth, GA. Sequencing was performed in the forward and
reverse directions with two or more primers covering each 250base pair section of the RT-encoding region along with small
flanking regions on either end of RT. Four different primers were
used to sequence the 2474 region containing the point mutation. This
DNA was directly sequenced by Joan Strange, The Murdock Molecular
Biology Facility, The University of Montana, Missoula, MT, with a Taq
Dye Deoxy™ Terminator sequencing kit and analyzed on a Model 373A
automated DNA sequencer (Applied Biosystems, Foster Gity, GA).

REVERSION STUDIES.

The

stability of the d4T-resistant

phenotype was determined for D4R-3c and D4R-4c. These mutants
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were passaged in the absence of d4T.

CrFK cells were infected with

D4R-3C, or D4R-4c and maintained without d4T. When virus
production was apparent (about two weeks), an

IC50

for d4T was

determined by FIA. The resulting viruses were used to initiate a
subsequent round of infection. Each virus was passaged three times
in the absence of d4T.

SITE-DIRECTED MUTAGENESIS.

To facilitate mutational analysis,

we constructed a 34pol cassette virus from the infectious molecular
clone, FIV 34TF10 (56). This was constructed by modification of the
EcoR1 site in the polylinker of FIV 34TF10, enabling use of the
natural EcoR1 site of the virus for the pol cassette. The EcoR1 site
in the polylinker was changed from GAATTC to GAATTG. This
modification was achieved by PGR using four synthetic primers.
Primer #144 was the most 5' and spanned the Dralll site of the
pUG119 portion of 34TF10 clone (5'-GAT TGG GTG TGA TGG TTC AGG
TAG TGG G-3'). Primer #145 was an antisense primer that spanned
the Eco R1 site of the vector's polylinker and changed this site (5'GAA TTG ACT GGC CGT CGT CGT TTT AC-3', base change underlined).
Primer #146 was a sense primer that matched primer #145 at the
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Eco R1 site and was also designed to alter the natural EcoR^ site
(5'-GTA AAA CGA CGG GCC AGT ÇAA TTC-3', base change underlined).
Primer #147 was the most 3' and spanned the Sac! site of the virus
(5'-CAA CTT GAT TAT GGA GOT CGA TG-3'). Primer pairs #144 /
#145 and #146 / #147 were used for PGR to amplify DNA from the
34TF10 target. Amplified DNA products were gel-purified, combined,
and reamplified using primers #144 and #147. The resulting PGR
product and 34TF10 were cleaved with Dralll and Sac\ and the
digests were gel-purified then ligated. The desired mutation was
confirmed by sequence analysis. After transfection into CrFK cells,
34pol cassette produced FIV that was indistinguishable from FIV
34TF10.

To introduce the mutation at codon 47 of the FIV RT, an 1164-bp
fragment corresponding to nucleotide 1740-2904 was amplified
using primer #16 (GAT CCT ATA TA A ATG TCA TCC) and primer #41
(GGA TCA GGA CCA GTG TGT). Amplification was performed using the
Perkin-Elmer/Cetus GeneAMP PCR protocol. Each 100 |il reaction
contained 10 mM Tris-HCI, pH8.3, 50 mM KCI, 200 |ilVI of each dNTP
(dATP, dCTP, dGTP and dTTP), 4 mM MgCb, 0.2 |iM of each primer, 2.5
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Units of AmpHTaq ® DNA polymerase, and 10 to 20 p.g of target DNA.
Reactions were overlaid with 50-100 p,l of light mineral oil. The
PGR was run for 30 cycles, each cycle comprised of 30 seconds of
denaturation at 94° G, 30 seconds of annealing at 52° G and two
minutes of extension at 72° G. After PGR, product was visualized on
an agarose gel. For this, the mineral oil was separated from the PGR
products and an aliquot of

the mixture was run on a 0.8% low-

melting agarose electrophoresis gel in 40 mM Tris acetate, pH 7.6
containing 1 mM EDTA (61). The agarose gel and running buffer
contained 0.5 |ig/ml ethidium bromide. The PGR product and 34pol
cassette were each cleaved with EcoRI and Nsi\. The reaction
contained 10X A/s/l buffer, 24 U EcoRI, 30 U Nsi\ and 3.6 mg of the
PGR product (including FIV 34TF10 or D4R-3c DNA) and then
incubated 3 hours at 37° G. The fragments were gel-purified by gene
cleaning. First, the gel slices were cut, and weighed. Then 3 volume
of sodium iodide were added and incubated 5 min at 45-55 °G. 5 |il
of glassmilk was added and incubated at room temperature for 30
min. After centrifugation, pellets were washed three times with
NEW wash (ethanol, both glassmilk and NEW wash are from BIO 101
gene-clean kit) and eluted with 20 )il of water. OD260 was measured.
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The resulting 803-bp fragment from D4R-3c, corresponding to
nucleotide 1871-2674 of the FIV genome, was ligated into the
cleaved 34pol cassette by using \^ector:insert ratio 1:4, adding T4
DNA ligase and incubating overnight at 16° C. DNA sequence analysis
was used to confirm the presence of the desired mutation. Only one
ligation product contained the 2474 point mutation. This construct
was transformed into the J5 strain of E. coli JM109 and the
resulting plasmid DNA was used to transfect CrFK cells for
production of virus.

RESULTS

SELECTION OF d4T-RESISTANT MUTANTS.

In initial

experiments, we attempted to obtain d4T-resistant mutants of FIV
by selection in the continuous presence of a high concentration of
d4T (100 |iM, which is approximately 8 times the

IC50

for FIV). This

approach, which we call "blast" selection, had been successful for
selection of FIV mutants resistant to AZT (57,58), ddl (21) or ddC
(43). However, in attempts to select with 100 |iM d4T, we were
unable to obtain any d4T-resistant mutants. Virus obtained after
this selection had wild type susceptibility to d4T. Therefore, we
switched to a step-wise selection protocol that is similar to that
used by Gao et al. (19,20) and by Larder et al. (36) to select drugresistant variants of HIV-1. The initial round of selection was
carried out with 12.5 |j.M d4T, which is equivalent to the IC50 of d4T
for FIV (58). The concentration of d4T was then increased 2-fold in
each subsequent round. For the first round of selection, two 25 cm2
flasks of 60% confluent CrFK cells were pre-treated with 12.5 |iM
d4T for 1 h prior to infection to ensure that the drug had been
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converted to its active form by the cells. Then the drug pre-treated
CrFK cells were infected with a cell-free culture supernatant of FIV
34TF10 at an input multiplicity of approximately 2000 focus
forming units (FFU). Media and drug were replaced every 48 hours,
and cells were removed with trypsin and subcultured as necessary
(usually every week). Cultures were monitored weekly for the
presence of virus by the FIA. By 2 to 3 weeks post-infection virus
production was apparent.

For the second round of selection, culture supernatants (cellfree) from each of the first-round cultures (approximately 2000 FFU
also) were used to infect flasks of CrFK cells in the presence of 25
|iM d4T. They were maintained with 25 |xM d4T and monitored for
virus production as before. Using these protocols, virus was
subsequently passaged in 50 and 100 iiM d4T, In each round of
selection, virus production was apparent by 2 to 3 weeks post
infection. After passage in 100 |iM d4T, dose response curves were
performed for preliminary screening of the d4T-resistant phenotype.
Two d4T-resistant mutants, designated D4R-1c and D4R-2c, were
obtained. These mutants were resistant to d4T (Fig. 5). At this point
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d4T DOSE RESPONSE CURVE FOR D4R-1c, AND 2c
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Fig 5. Inhibition of FIV 34TF10, D4R-1c and D4R-2c by d4T as
determined by FIA. Results are from two experiments and each point
represent four determinations. Bars represent standard error of the
mean, and are omitted where the standard error was too small to
accurately show using error bars.
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plaque-purification of mutant viruses were initiated.

PLAQUE-PURIFICATION OF d4T-RESISTANT MUTANTS. To
minimize potential heterogeneity within the d4T-resistant mutant
populations, the FIA was used to isolate a clone of virus that had
descended from a single infectious particle. A focus of infection
represents an infection by a single virion (Fig. 6).

Fig 6. Focus of FIV-infected CrFK cells detected with the
immunostaining procedure described in methods.

CrFK cells were seeded at a density of 1.0 X 104 cells per well in
TC24 plates, with 100 |iM d4T, and were infected with virus stocks
(D4R-1C and D4R-2c) that had been diluted to contain approximately
one infectious particle per well. After six days, culture
supernatants were transferred to uninfected cells with 100 |a,M d4T
in TC24 plates, and the original plates were immunostained to
identify those wells that contained a single focus of infection. Cells
infected with progeny from a single infection event were
transferred along with supernatant to a flask and maintained with
100 fiM d4T and monitored for virus production by the FIA. Two
plaque-purified mutants, designated D4R-3c and D4R-4c (obtained
from D4R-1C and D4R-2c, respectively) were selected for further
characterization. Both plaque-purified mutants retain the d4Tresistant phenotype of the parent populations (Fig. 7).

The d4T-resistance of the D4R-1c, D4R-2c, D4R-3c and D4R-4c
were confirmed with the FIA by determining the number of foci at
varying concentrations of d4T. The dose response curves shown in
Fig. 5 and Fig. 7 verify that D4R-1c, 2c and D4R-3c, 4c were
considerably

less sensitive to

inhibition

by d4T than the molecular
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d4T DOSE RESPONSE CURVE FOR D4R-3c, AND 4c
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Fig 7. Inliibition of FIV 34TF10 and D4R-3c and 4c by d4T as
determined by FIA. Results are from three experiments and each
point represent four determinations. Bars represent standard error
of the mean, and are omitted where the standard error was too small
to accurately show using error bars.

clone of FIV. The

IC50

value for inhibition of D4R-1c and 2c by

d4T were greater than 36 |iM compared to 12

for FIV 34TF10.

Similar results were determined with D4R-3c and D4R-4c. These
data demonstrated that these mutants were at least 3 to 6-fold less
susceptible to d4T than FIV 34TF10.

CHARACTERIZATION

OF d4T-RESISTANT MUTANTS.

Susceptibility to antiviral compounds.
D4R-3C and D4R-4c

The susceptibility of

to a variety of other antiviral compounds was

determined using the FIA and compared to the susceptibilities of FIV
34TF10 (Fig 8. and Table. 1). These data showed that D4R-3c and
D4R-4C were cross-resistant to several other antiviral compounds.
Both mutants were 2 to 2.5-fold resistant to AZT, 5 to 6-fold
resistant to FLT, 2-fold to ddC, 1 to 2 fold to ddl and 4-fold to PMEA.
They were also highly resistant (>50-fold) to the non-nucleoside
inhibitor, PFA.

48

34TF10
D4R-3C
D4R-4C

20 34TF10
Q _ -a- D4R-3C
—Ar- D4R-4C

O
o
LL
o
cr

ë
o
o
5?

100

120

- 34TF10
- D4R-3C
D4R-4C

60 -

40 -

34TF10
OdR-Sc
D4R-4C
1
[ddl] (pM)

[FLT] []iM)
F

34TF10
D4R-4C
34TF10
-* - D4R-3C
-Ar- D4R-4C
0.1

1
[PMEA] (pM)

10

10

100

1000

[PFA] (pM)

Fig 8. Inhibition of FIV 34TF10 and D4R-3c and 4c by various
antivirals as determined by FIA. Results are from three experiments
and each point represent four determinations. Bars represent
standard error of the mean, and are omitted where the standard
error was too small to accurately show using error bars.
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Table 1.

Sensitivities of FIV 34TF10 and d4T-resistant mutants

derived from it to antiviral compounds as determined by FIAa

MEAN IC50

+ SE

Compound

FIV 34TF10

D4R-3c

D4R-4c

d4T

9±2

34 ±8

32 ± 7

AZT

0.3 ±0.1

0.8 ±0.1

0-7 ± 0.1

FLT

0.2 ± 0.05

1.1 ± 0.1

1.3 ± 0-1

ddC

4.4 ± 0.3

9.1 ± 1.5

9 ± 2.1

ddl

1.1 ± 0.04

2.4 ± 0.4

1.5 ± 0

PFA

207 ± 44

>10,000

>10,000

PMEA

0.1 ± 0

0.4 ± 0.02

0.4 ± 0-02

^Values are from two or more experiments, with four
determinations per experiment.
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Reverse transcriptase.

Reverse transcriptase was purified from

D4R-3C and from wild-type FIV (recombinant RT) (46). This wildtype FIV RT was produced in Escherichia coli, and has been shown to
be similar to virion-derived FIV RT in its susceptibility to several
antiviral nucleotides. The kinetic parameters of inhibition by

d4TTP

were determined for D4R-3c RT and compared to wild-type FIV RT.
The two enzymes were nearly identical in Km for dTTP (5.8 ±0.6 |j,M).
However, the Kj for inhibition of RT from D4R-3c by d4TTP, 4 7 nM,
was 3-times higher than that of wild-type FIV RT. Furthermore, the
Ki values for inhibition of this mutant enzyme and R-RT by AZTTP
and PFA were determined. As expected, AZTTP and d4TTP displayed
competitive inhibition of the enzymes and PFA displayed non
competitive inhibition (Fig. 9). The inhibition constant of mutant RT
by AZTTP, 21 nM, was 10-times higher than that of wild-type FIV RT
and by PFA,1.7 |iM, was 6-times higher than for inhibition of the
wild-type FIV RT, respectively (Table 2).
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Table 2.

Kinetic Constants for wild-type FIV and D4R -3c RTs a

Ki rnM^
Inhibitor

FIV 34TF10 RT

D4R-3c-RT

d4TTP

1.4 + 0.14

4.7 + 0.16

AZTTP

2.2 ± 0.23

21 + 1.51

RFA

265 ± 37

1720 + 345

^Values are reported as the mean + SEM of at least five
determinations. The mode of inhibition of each enzyme by d4TTP or
by AZTTP was competitive with respect to substrate. Inhibition of
each enzyme by PFA was non-competitive with respect to substrate.
The Km for dTTP was 5.8 + 0.6 jiM for each enzyme.
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Fig 9. Determination of K, values for inhibition of wild-type FIV RT
and D4R-3C RT. Values reported are averages from duplicate
determinations.

53
Nucleotide sequence analysis.

DNA sequence analysis of the

entire RT-encodIng region of the pol gene from D4R-3c and FIV
34TF10 were perfornned in the forward and reverse directions. FIV
34TF10 DNA had been subcloned into the plasmid pUC119 and was
used as the wild-type control. These analyses revealed only a single
point mutation, a G to A base change, at position 2474 of the FIV pol
gene. This substitution results in the replacement of Val-47 with
lie, named 147. The nucleic acid and amino acid sequences of FIV
34TF10 and D4R-3c pol gene are shown in Fig. 10
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Fig. 10 Nucleotide sequence and deduced amino acid sequence of RTencoding region of pol gene from FIV 34TF10 clone of FIV in
pUC119, virus derived from this molecular clone and D4R-3c.
denotes identity.
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Reversion studies.

In order to determine whether this 147

mutation was genetically stable, CrFK cells were infected with
D4R-3C and D4R-4c and maintained in the absence of d4T. When virus
production was apparent, an

IC50

for d4T were determined, and these

viruses were used to initiate a subsequent round of infection. This
experiment was carried out for three rounds of infection. Both
viruses remained d4T-resistant even after three rounds without d4T
(Table. 3). These data demonstrated that the d4T-resistant
phenotype is stable.

Site-directed

mutagenesis.

In order to confirm the role of this

mutation in d4T-resistance, the G to A mutation at position 2474
was introduced into the FIV 34pol cassette by site-directed
mutagenesis. Initial attempts to obtain a 1297-bp fragment from
D4R-3C proviral DNA with primers #28 and #16 were not successful.
Therefore, we switched to primers #41 (GGATCAGGACCAGTGTGT)
and #16 (GATCCTATATAAATGTCATCC) and obtained an 1164-bp
fragment containing position 2474. This fragment and 34pol
cassette were each cleaved with EcoRI and Nco\, and ligated. After
transforming them into the J5 strain of E. coli JM109, there were no
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Table 3.

Phenotypic stability of d4T-resistant mutants when

passaged in the absence of d4T a

MEAN IC50 (iliM) ± SEM

Virus

Roundl

Round2

Round3

34TF10

12.8 ± 2.8

16 ± 2.7

14 ± 3.1

D4R-3C

24.5 ± 5.5

33 ± 3.3

63 ± 26

D4R-4C

38 ± 13

24 ± 4.8

41.3+12

^Values are from two or more experiments with four determinations
per experiment.

colonies. EcoRI and Nsi\ were then used in a second attempt, and
five colonies were obtained.

DNA sequence analysis revealed that

one colony had the correct insert containing the 147 mutation. This
DNA was transfected into CrFK cells. When virus was apparent, an
IC50 for d4T was determined. The mutant made by site-directed
mutagenesis was 2.5-fold resistant to d4T, confirming the role of
this mutation in d4T-resistance.

DISCUSSION

The results of this study have demonstrated the in vitro selection
and characterization of d4T-resistant mutants of FIV. This was the
first d4T-resistant mutant derived from a molecular clone of either
FIV or HIV-1. We initially attempted to select d4T-resistant
mutants with a "blast" protocol. Using this method, AZT, ddl and
ddC-resistant mutants of FIV were successfully selected.

However,

we were unable to obtain any d4T-resistant mutants from this type
of selection. The virus that was obtained after passaged in 100 |j,M
d4T was quickly apparent after 1 to 2 weeks, and was as susceptible
to d4T as the wild-type strain,

FIV 34TF10.

The reason for this

may be incomplete inhibition of wild-type virus. Therefore, we
switched to a step-wise selection protocol, and succeeded in
selection of d4T-resistant mutants of FIV.

The d4T-resistant mutants we have isolated have relatively low
level, i.e. 3- to 6-fold, resistance to d4T. This level of resistance is
similar to that reported by Lacey and Larder for a d4T-resistant
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mutant of HIV-1, which displayed 7-fold resistance (33). Relatively
low level resistance has also been observed with mutants for FIV or
HIV-1 resistant to ddl or ddC. For example, a ddl-resistant mutant of
FIV displayed a

2 to 4-fold less susceptibility to ddl (21), ddC-

resistant mutant of FIV was 3 to 6-fold resistant to ddC (43), and
the HIV-1 mutants resistant to ddl or ddC range from 4 to 6-fold
resistant (18,19,20,23,64). In

contrast, many of the AZT-resistant

mutants of FIV (57,58) or HIV-1 (35,36,37) displayed greater than
40-fold resistance to AZT.

The plaque-purified d4T-resistant mutants we have isolated are
cross-resistant to ddl and ddC. In this respect they are
phenotypically similar to the d4T-resistant mutant of HIV-1
reported by Lacey and Larder (33). The d4T-resistant mutants of FIV
were also cross-resistant to AZT, FLT, PMEA and PFA. However,
Lacey and Larder reported that the d4T-resistant mutant of HIV-1
remained sensitivity to AZT and they did not determine FLT, PMEA
and PFA.
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Reverse transcriptases were purified from wild-type and the
plaque-purified d4T-resistant mutant (D4R-3c) of FIV. The RT from
the mutant virus was resistant to the active form of d4T, d4TTP.
The mutant enzyme had a 3-fold higher Kj for d4TTP than the wildtype FIV RT, whereas the two enzymes were identical in K m for the
substrate, dTTP. This 3-fold resistance at the enzyme level
correlates well with the 3- to 6-fold resistance at the level of
virus replication. Moreover, we found that D4R-3c RT also had
decreased susceptibility to inhibition by AZTTP or PFA.
Interestingly, the level of the RT resistance to AZTTP was greater
than the level of resistance to AZT of virus replication. A similar
lack of correlation between virus susceptibility to AZT and RT
susceptibility to AZTTP has been shown for many AZT-resistant
mutants of HIV-1 and FIV, which have RTs that are not even
resistant to AZTTP (36,37,57).

The resistance shown by the RT from D4R-3c is due to a mutation
in the RT-encoding region of the FIV pol gene. Sequence analysis of
the plaque-purified d4T-resistant mutant of FIV revealed a single
point mutation resulting in an amino acid change from valine to
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isoleucine at codon 47 of FIV RT. This nucleotide substitution at
position 2474 in D4R-3c was the only divergence from the wild-type
RT-encoding region. The d4T-resistant mutant of HIV-1 that has
been characterized was mapped to codon 75 of the HIV-1 RT (33),
and there have been no drug-resistant mutants of HIV-1 or FIV RTs
that map to codon 47 (62). Interestingly,
codon 47 of RT from the d4T-resistant

the amino acid found at
mutant of FIV (isoleucine) is

the amino acid present at codon 47 of wild-type HIV-1 RT. It will be
interesting to determine whether alteration of codon 47 in the HIV1 RT will affect susceptibility of HIV-1 to d4T or other RT-targeted
antiviral drugs.

Some AZT-resistant mutants of FIV that phenotypically revert
very rapidly when they replicate in the absence of AZT (58). In
contrast, D4R-3c (like a ddC-resistant mutant of FIV, DCR-5c) (43)
remained phenotypically stable when passaged in the absence of d4T,
even after three passages. This genetic stability makes D4R-3c a
better candidate than the genetically unstable mutants for future in
vivo

studies to evaluate how mutations conferring drug-resistance

affect pathogenicity of the virus.
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The structure of HIV-1 RT has been determined by X-ray
crystallography (29,31). Many reports have shown crystals of RT
suitable for structural analysis. HIV-1 RT contained two subunits,
p66 and p51. The p66 subunit is folded into five separate
subdomains, the RNase H domain and four subdomains of the pol
domain, termed fingers, palm, thumb and connection. p51 has the
same amino acid sequence and subdomains, but the conformation of
the pol domain is astonishingly different from that of p66 (31).
Based upon the X-ray crystal structure of HIV-1 RT and the amino
acid sequence homology of the HIV-1 and FIV RTs, codon 47 is
predicted to be in the "fingers domain" of RT. On the p66 subunit
this is on the outside of the "fingers domain", whereas the active
site of the enzyme is on the opposite, or inner side of the "fingers".
However, position 47 of the p51 subunit is adjacent to the active
site of the p66 subunit, in a position where a mutation of this amino
acid could affect drug susceptibility. Based upon the available
structural data, we predict that the mutation in codon 47 of the p51
subunit is responsible for the altered susceptibility of RT to several
nucleotide analogs.
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Due to the emergence of mutants resistant to any of the drug used
in monotherapy, much effort is currently focused upon evaluation of
combinations of two or more drugs. Recently, chemotherapy of HIV
infections, as for other chronic infections and malignant diseases,
is moving into the direction of multiple drug combinations. The
major advantages of this is: non-overlapping toxicities, reduced risk
of viral-drug resistance development, and the possibility of
synergistic combinations. The demonstration that d4T-resistant FIV
has decreased susceptibility to several other RT inhibitors suggests
that mutants resistant to the combination of d4T with another RT
inhibitor may arise readily. Thus, d4T may not be suitable for use in
these multiple drug combinations.

CONCLUSION

Two d4T resistant mutants (D4R-1c, D4R-2c) were successfully
obtained by step-wise selection with 100 |iM final d4T
concentration. D4R-1c and 2c were plaque-purified and the resulting
viruses, designated D4R-3c and 4c. All of these mutants were at
least 3-fold resistant to d4T as compared to FIV 34TF10. They were
also cross-resistant to AZT, FLT, ddC, ddl, and PMEA, and were
highly resistant to PFA. Purified D4R-3c RT was 3-fold resistant to
d4TTP, 10-fold to AZTTP and 6-fold to PFA, relative to wild type
FIV RT. A single point mutation was found in the d4T-resistant
mutant (D4R-3c) that resulted in the amino acid substitution of He
for Val at codon 47 of the FIV RT. The phenotype of d4T-resistant
mutants was stable, as D4R-3c and D4R-4c remained d4T-resistant
even after passage in the absence of d4T for three rounds. The role
of the V to I mutation at codon 47 in d4T-resistance was confirmed
by site-directed mutagenesis.

Future studies should evaluate whether multiple-drug resistant
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mutants will arise more rapidly with combinations containing d4T.
It will also be important to examine pathogenicity of d4T-resistant
FIV, and other FIV drug-resistant mutants, in cats.

REFERENCES

1.

Amacker, M., M. Hottiger, and U. Hubscher. 1995. Feline
Immunodeficiency virus reverse transcriptase: expression,
functional characterization, and reconstitution of the 66- and
51-kilodalton subunits. J. Virol. 69:6273-6279.

2.

Anderson, R., C. Wirtz, A. Cross, M. Adier, R. Brunell, and L.
Dunkle. 1993 Program Abstr. 33rd Intersci. Conf. Antimicrob.
Agents Chemother., abstr. 684.

3.

August, E.M., E.M. Birks, and W.H. Prusoff. 1991. 3'deoxythymidine-2'-ene permeation of human lymphocyte H9
cells by nonfacilitated diffusion. Mol. Pharmacol. 39:246-249.

4.

Baba, M., R. Parwels, P. Herdewjn, E. De Clercq, J. Desmyter, and
M. Vandeputte. 1987. Both 2',3'-dideoxythymidine and its 2',3'unsaturated derivative (2',3'-dideoxythymidinene) are potent
and selective inhibitors of human immunodeficiency virus
replication in vitro. Biochem. Biophys. Res. Commun. 142:128134.

5.

Balzarini, J., G.-J. Kang, M. Dalai, P. Herdewijn, E. De Clercq, S.
Broder and D.G. Johns. 1987. The anti-HTLV-lll (Anti-HIV) and
cytotoxic activity of 2',3'-didehydro-2',3'dideoxyribonucleosides: A comparison with their parental
2',3'-dideoxyribonucleosides. Mol. Pharmacol. 32:162-167.

6.

Balzarini, J., P Herdewijn and E. De Clercq. 1989. Differential
patterns of intracellular metabolism of 2',3'-didehydro-2',3'dideoxythymidine and 3'-azide-2',3'-dideoxythymidine, two
potent anti-human immunodeficiency virus compounds. J. Biol.
Chem. 264:6127-6133.

70

71
7.

Barlough, J.E., T.W., North, C.L Oxford, K.M. Remington, S.
Dandekar, M. Nixon Ellis, and N.C. Pedersen. 1993. Feline
immunodeficiency virus infection of cats as a model to test
the effect of certain in vitro selection pressures on the
infectivity and virulence of resultant lentivirus variants.
Antiviral Res. 22:159-272.

8.

Bendinelli, M., M. Pistello, S. Lombardi, A. Poli, C. Garzelli, D.
Matteucci, L. Ceccherini-Nelli, G. Malvaldi, and F. Tozzini. 1995.
Feline immunodeficiency virus; an interesting Model for AIDS
studies and an important cat pathogen. Clin. Microbiol. Rev.
8:87-112.

9.

Chesebro, B., and K. Wehrly. 1988. Development of a sensitive
quantitative focal assay for human immunodeficiency virus
infectivity. J. Virol. 62:3779-3788.

10.

Condra, J.H., W.A. Schieif, O.M. Blahy, L.J. Gabryelski, D.J.
Graham, J C. Quintero, A. Rhodes, H.L. Robbins, E. Roth, M.
Shivaprakash, D. Titus, T. Yang, H. Teppler, K.E. Squires, P.J.
Deutsch and E.A. Emini. 1995. In vivo emergence of HIV-1
variants resistant to multiple protease inhibitors. Nature
374:569-571.

11.

Cronn, R.C., K.M. Remington, B.D. Preston and T.W. North. 1992.
Inhibition of reverse transcriptase from feline
immunodeficiency virus by analogs of 2'-deoxyadenosine-5'triphosphate. Biochem. Pharmacol. 44:1375-1381.

12.

De Clercq E. 1989. New acquisitions in the development or
anti-HIV agent. Antiviral Res. 12:1-20.

13.

De Clercq, E. 1992. HIV inhibitors targeted at the reverse
transcriptase. AIDS Res Human Retroviruses. 8:119-134.

72
14.

Egberink, H.F., J. Ederveen, R.C. Montelaro, N.C. Pedersen, M.C.
Horzinek, and M.J.M. Koolen. 1990. Intracellular proteins of
feline immunodeficiency virus and their antigenic relationship
with equine infectious anemia virus proteins. J. Gen. Virol.
71:739-743.

15.

Elder, J.H., D.A. Lerner, C.S. Hasselkus-Light, D.J. Fontenot, E.
Hunter, P.A. Luciw, R.c. Montelaro, and T.M. Phillips. 1992.
Distinct subsets of retroviruses encode dUTPase. J. Virol.
66:1791-1794.

16.

Elder, J.H., M. Schnolzer, C.S. Hasselkus-Light, M. Henson, D.A.
Lerner, T.R. Phillips, P.C. Wagaman, and S.B.H. Kent. 1993.
Identification of proteolytic processing sites within the Gag
and Pol polyproteins of feline immunodeficiency virus. J. virol.
67:1869-1876.

17.

Faulds, D., and R.N. Brogden. 1992. Didanosine. A review of its
antiviral activity, pharmacokinetic properties and therapeutic
potential in human immunodeficiency virus infection. Drugs
44:94-116.

18.

Fitzgibbon, J.E.,R.M. Howell, C.A. HaberzettI, S.J. Sperber,
D.J.Gocke and D.T.Drbin. 1992. Human immunodeficiency virus
type 1 pol gene mutations which cause decreased
susceptibility to 2',3'-dideoxycytidine. Antimicrob. Agents
Chemother. 36:153-157.

19.

Gao, Q., Z. Gu, J. Hiscott, G. Dionne and M.A. Wainberg. 1993.
Generation of drug-resistant variants of human
immunodeficiency virus type 1 by in vitro passage in
increasing concentrations of 2',3'-dideoxycytidine and 2',3'dideoxy-3'-thiacytidine. Antimicrob. Agents Chemother.
37:130-133.

73
20.

Gao, Q., Z. Gu, M.A. Parniak, X. Li and M.A. Wainberg. 1992. In
vitro selection of variants of human immunodeficiency virus
type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'dideoxyinosine. J. Virol. 66:12-19.

21.

Gobert, J.M., K.M. Remington, Y.-Q. Zhu and T.W. North. 1994.
Multiple-drug-resistant mutants of feline immunodeficiency
virus selected with 2',3'-dideoxyinosine alone and in
combination with 3'-azido-3'-deoxythymidine. Antimicrob.
Agents Chemother. 38:861-864.

22.

Gogu, S R., Beckman and K.C. Agrawal. 1989. Anti-HIV drugs:
comparative toxicities in murine fetal liver and bone marrow
erythroid progenitor cells. Life Sci. 45:iii-vii.

23.

Gu, Z., Q. Gao, H. Fang, H. Salomon, M.A. Parniak, E. Goldberg, J.
Cameron and M.A. Wainberg. 1994. Identification of a mutation
at codon 65 in the IKKK motif of reverse transcriptase that
encodes human immunodeficiency virus resistance to 2',3'dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob.
Agents Chemother. 38:275-281.

24.

Hitchcock, M.J.M. 1991. 2',3'-Didehydro-2',3'-dideoxythymidine
(D4T), an anti-HIV agent. Antiviral Chem. Chemother. 2:125132.

25.

Ho, H.-T., and M.J.M. Hitchcock. 1989. Cellular pharmacology of
2',3'-dideoxy-2',3'-didehydrothmidine, a nucleoside analog
active against human immunodeficiency virus. Antimicrob.
Agents Chemother. 33:844-849.

26.

Hopper, C.D., A.H. Sparkes, T.J. Gruffydd-Jones, S. M. Crispin, P.
Muir, D.A. Harbour, and C.R. Stokes. 1989. Clinical and
laboratory findings in cats infected with feline
immunodeficiency virus. Vet. Rec. 125:341-346.

27.

Ishida, T., and I. Tomoda. 1990. Clinical Staging of feline
immunodeficiency virus infection. Jpn. J. Vet. Sci. 52:645-648.

74
28.

Jacobsen, H., K. Yasargil, D.L Winslow, J.C. Craig, A. Krohn, I.B.
Duncan and J. Mous. 1995. Cliaracterization of fiuman
immunodeficiency virus type 1 mutants with decreased
sensitivity to proteinase inliibitor Ro 31-8959. Virology
206:527-534.

29.

Jocobo-Molina, A., J. Ding, R.G. Nanni, A.D. Clark, Jr., X. Lu, C.
Tantillo, R.L. Williams, G. Kamer, A.L. Ferris, P. Clark, A. Hizi,
S.H. Hughes and E. Arnold. 1993 Crystal structure of human
immunodeficiency virus type 1 reverse transcriptase
complexed with double-stranded DNA at 3.0 Â resolution shows
bent DNA. Proc. Natl. Acad. Sci. USA 90:6320-6324.

30.

Kaplan, A.M., S.F. Michael, R.S. Wehbie, M.F. Knigge, D.A. Pari, L.
Everit, D.J. Kempf, D.W. Norbeck, J.W. Erickson and R.
Swanstrom. 1994. Selection of multiple human
immunodeficiency virus type 1 variants that encode viral
proteases with decreased sensitivity to an inhibitor of the
viral protease. Proc. Natl. Acad. Sci. USA 91:5595-5601.

31.

Kohlstaedt, LA., J. Wang, J.M. Friedman, P.A. Rice and T.A.
Steitz. 1992. Crystal structure at 3.5 Â resolution of HIV-1
reverse transcriptase complexed with an inhibitor. Science
256:1783-1790.

32.

LaCasse.A., K.M. Remington, and T.W. North. 1996. AZT
enhances the mutation frequency of feline immunodeficiency
virus. J. Acquir. Immune Defic. Syndr. Human Retrovirol. (in
press).

33.

Lacey, S.F., B.A. Larder. 1994. Novel mutation (V75T) in human
immunodeficiency virus type 1 reverse transcriptase confers
resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell
culture. Antimicrob. Agents Chemother. 38:1428-1432.

34-

Langtry, H.C., and D.M. Campoli-Richards. 1989. Zidovudine. A
review of its pharmacodynamic and pharmacokinetic
properties, and therapeutic efficacy. Drugs 37:408-450.

75
35.

Larder, B.A., G. Darby and D.D. Richman. 1989. HIV with reduced
sensitivity to zidovudine (AZT) isolated during prolonged
therapy. Science 243:1731-1734.

36.

Larder, B.A., K.E. Coates and S.D. Kemp. 1991. Zidovudineresistant human immunodeficiency virus selected by passage
in cell culture. J. Virol. 65:5232-5236.

37.

Larder, B.A., and S.D. Kemp. 1989. Multiple mutations in HIV-1
reverse transcriptase confer high-level resistance to
zidovudine (AZT). Science 246:1155-1158.

38.

Lever, A.M.L. 1995. Gene therapy for HIV infection. Br. Med. Bull.
51:149-166.

39.

Lin, T.-S., R.F. Schinazi,and W.H. Prusoff. 1987. Potent and
selective in vitro activity of 3'-deoxythymidine-2'-ene(3'deoxy-2',3'-didehydrothymidine) against human
immunodeficiency virus. Biochem. Pharmacol. 36:2713-2718.

40.

Mansuri, M.M., J E. Starrett, Jr., I. Ghazzouli, M.J. Hitchcock, R.Z.
Sterycki, V. Brankovan, T.-S. Lin, E.M. August, W.H. Prusoff, J.P. Sommadossi and J.C. Martin. 1989. 1-(2,3-Dideoxy-3-Dglycero-pent-2-enofuranosyl) thymine. A highly potent and
selective anti-HIV agent. J. Med. Chem. 32:461-466.

41.

Mansuri, M.M., M.J Hitchcock, R.A. Buroker, C.L. Bregman, I.
Ghazzouli, J. V. Kesiserio, J.E. Starrett, R.Z. Sterzycki and J.C.
Martin. 1990. Comparison of in vitro biological properties and
mouse toxicities of three thymidine analog active against
human immunodeficiency virus. Antimicrob. Agents Chemother.
34:637-641.

42.

Marongiu, M.E., E.M. August, and W.H. Prusoff. 1990. Effect of 3'deoxythymidine-2'-ene (D4T) on nucleoside metabolism in H9
cells. Biochem. Pharmacol. 39:1523-1528.

76
43.

Medlin, H.K., Y.-Q. Zhu, K.M. Remington, T.R. Phillips and T.W.
North. 1996. Selection and characterization of a mutant of
feline immunodeficiency virus resistant to 2',3'dideoxycytidine. Antimicrob. Agents Chemother. 40:953-957.

44-

Mitsuya, H., R. Yarchoan, and S. Broder. 1990. Molecular targets
for AIDS therapy. Science 249:1533-1544.

45.

Miyazawa, T., T Furuya, S.-l. Itagaki, Y. Tohya, K. Nakano, E.
Tadahashi, and T Midami. 1989. Preliminary comparisons of the
biological properties of two strains of feline
immunodeficiency virus (FIV) isolated in Japan with FIV
Petaluma strain isolated in the United States. Arch. Virol.
108:59-68.

46.

North, T.W., G.L. Hansen, Y-Q. Zhu, J.A. Griffin, and C -K. Shih.
1994. Expression of reverse transcriptase from feline
immunodeficiency virus in Escherichia coli. Antimicrob. Agents
Chemother. 38:388-391.

47.

North, T.W., G.L.T. North, and N.C. Pedersen. 1989. Feline
immunodeficiency virus: a model for reverse transcriptasetargeted chemotherapy for acquired immune deficiency
syndrome. Antimicrob. Agents Chemother. 33:915-919.

48.

North, T.W., R.C. Cronn, K.M. Remington, and R.T. Tandberg. 1990.
Direct comparisons of inhibitor sensitivities of reverse
transcriptases from feline and human immunodeficiency
viruses. Antimicrob. Agents Chemother. 34:1505-1507.

49.

North, T.W., R.C. Cronn, K.M. Remington, R.T. Tandberg, and R.C
Judd. 1990. Characterization of reverse transcriptase from
feline immunodeficiency virus. J. Biol. Chem. 265:5121-5128.

50.

Novello, A.C. 1993. The HIV/AIDS epidemic: A current picture.
J. AIDS. 6:645-654.

77
51.

Otto, M.J., S. Garber, D L. Winslow, C.D. Reid, P. Aldrich, P.K.
Jadhav, C.E. Pattersen, C.N. Hodge and Y.-S. E. Cheng. 1993. In
vitro isolation and identification of human immunodeficiency
virus (HIV) variants with reduced sensitivity to C-2
symmetrical inhibitors of HIV type 1 protease. Proc. Natl.
Acad. Sci. USA 90:7543-7547.

52.

Pedersen, N.C. 1993. Feline immunodeficiency virus infection.
In J.A. Levy (ed.). The retroviruses, vol. 2. Plenum Press, New
York.

53.

Pedersen, N.C., E.W. Ho, M.L Brown, and J.K. Yamamoto. 1987.
Isolation of a T-.ymphotropic virus from domestic cats with an
immunodeficiency-like syndrome. Science 235:790-793.

54.

Pedersen, N.C., J.K. Yamamoto, T. Ishida, and H. Hansen. 1989
Feline immunodeficiency virus infection. Vet. Immunol, and
Immunopath. 21:111-129.

55.

Pluda, J.M., T.P. Cooley, J.S. Montaner, LE. Shay, N.E. Reinhalter,
S.N. Warthan, J. Ruedy, H.M. Hirst, C.A. Vicary, J.B. Qrinn. 1995.
A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in
patients with advanced human immunodeficiency virus
infection. J. Inf. Dis. 171:1438-1437.

56.

Phillips, T.R., R.L. Talbott, C Lamont, S. Muir, K. Lovelace, and
J.H. Elder. 1990. Comparison of two host cell range variants of
feline immunodeficiency virus. J. Virol. 64:4605-4613.

57.

Remington, K.M., B. Chesebro, K. Wehrly, N.C. Pedersen and T.W.
North, 1991. Mutants of feline immunodeficiency virus
resistant to 3'-azido-3'-deoxythymidine, J. Virol, 65:308-312.

58.

Remington, K,M., Y.-Q. Zhu, T.R. Phillips, and T.W. North. 1994.
Rapid phenotypic reversion of zidovudine-resistant feline
immunodeficiency virus without loss of drug-resistant reverse
transcriptase. J. Virol. 68:632-637.

78
59.

Richman, D.D. 1993. Resistance of clinical isolates of human
immunodeficiency virus to antiretroviral agents. Antimicrob.
Agents and Chemother. 37:1207-1213.

60.

Richman, D.D., Havlir, J. Corbeil, D. Looney, C. Ignacio, S.A.
Spector, J. Sullivan, S. Cheeseman, D. Barringer, D. Pauletti,
C.K. Shih, M. Myers and J. Griffin. 1992. Nevirapine resistance
mutations of human immunodeficiency virus type 1 selected
during therapy. J. Virol. 68:1660-1666.

61.

Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular
Cloning: A Laboratory Manual. Second edition. Coldspring Harbor
press, Coldspring Harbor, N.Y. 1:6.30-6.31.

62.

Schinazi, R., B. Larder and J Mellors. 1994. Mutations in HIV-1
reverse transcriptase and protease associated with drug
resistance. Int. Antiviral News 2:72-75.

63.

Shafer, R.W., M.J. Kozal, M.A. Winters, A.K.N. Iversen, D.A.
Katzenstein, M.V. Ragni, W.A.Meyer, P.Gupta, S. Rasheed, R.
Coombs, M. Katzman, S. Ficus and T.C- Merigan. 1994.
Combination therapy with zidovudine
and didanosine selects
for drug-resistant human immunodeficiency virus type 1
strains with unique patterns of pol gene mutations. J. Inf. Dis.
169:722-729.

64.

St. Clair, M.H., J.L. Martin, G. Tudor-Williams, M.C. Bach, C.L.
Vavro, D.M. King, P. Kellam, S.D. Kemp and B.A. Larder. 1991.
Resistance to ddl and sensitivity to AZT induced by a mutation
in HIV-1 reverse transcriptase. Science 253:1557-1559.

65.

Steinman, R., J. Dombrowski, T. O'Connor, R.C. Montelaro, Q.
Tonelli, K. Lawrence, C Seymour, J. Goodness, N.C. Pedersen,
and P.R. Andersen. 1990. Biochemical and immunological
characterization of the major structural proteins of feline
immunodeficiency virus. J. Gen. Virol. 71:701-706.

79
66.

Stephens, E.B., E. Monck, K. Reppas, and E.J. Butfiloski. 1991.
Processing of the glycoprotein of feline immunodeficiency
virus: effect of inhibitors of glycosylation. J. Virol. 65:11141123.

67.

Talbott, R.L, E.E. Sparger, K.M. Lovelace, W.M. Fitch, N.C.
Pedersen, P.A. Luciw, and J.H. Elder. 1989. Nucleotide sequence
and genomic organization of feline immunodeficiency virus.
Proc. Natl. Acad. Sci. USA 86:5743-5747.

68.

Temin, H.M. and D. Baltimore. 1972. RNA directed DNA synthesis
and RNA tumor viruses. Adv. Virus Res. 17:129-186.

69.

Tochikura, T.S., K. A. Hayes, C.M. Cheney, A. Tanabe-Tochidura,
J.L. Rojko, L.E. Mathes, and R.G. Olsen. 1990. In vitro replication
and cytopathogenicity of the feline immunodeficiency virus for
feline T4 thymic lymphoma 3201 cells. Virology 179:492-497.

70.

Torten, M., M Franchini, J.E. Barlough, J.W. George, E. Mozes, H.
Lutz, and N.C. Pedersen. 1991. Progressive immune dysfunction
in cats experimentally infected with feline immunodeficiency
virus. J. Virol. 65:2225-2230.

71.

Wainberg, M.A., Z. Gu, Q. Gao, E. Arts, R. Geleziunas, S. Bour, R.
Beaulieu, C. Tsoukas, J. Singer and J. Montaner. 1993. Clinical
correlates and molecular basis of HIV drug resistance. J.
Acquired Immune Defic. Syndr. 6 (Suppl. 1):S36-S46.

72.

Wasmoen, T., S. Armger-Luhman, C. Egan, B. Hall, H.-J. Chu, L.
Chavez, and W. Acree. 1992. Transmission of feline
immunodeficiency virus from infected queens to kittens. Vet.
Immunol, and Immunopath. 35:83-94.

73.

Whittington, R., and R.N. Brogden. 1992. Zaicitabine. A review
of its pharmacology and clinical potential in acquired
immunodeficiency syndrome (AIDS). Drugs 44:656-683.

80
74.

Yamamoto, U.K., E.Sparger, E.W. Ho, P.R. Andersen, T.P. O'Connor,
C.P. Mandell, L. Lowenstine, R. Munn, and N C. Pedersen. 1988.
Pathogenesis of experimentally Induced feline immuno
deficiency virus infection in cats. Am. J. Vet. Res.
49:1246-1258.

75.

Yamamoto, J.K., N.C. Pedersen, E.W. Ho, T. Okuda, and G.H.
Theilen. 1988. Feline immunodeficiency syndrome — a
comparison between feline T-lymphotropic lentivirus and
feline leukemia virus. Leukemia 2:2048-215S.

